Does Blinatumomab belong to the targeted drug category?

Blinatumomab (Blinatumomab) is a targeted drug, specifically a bispecific antibody drug. Its design and mechanism of action are designed to precisely target specific cancer cells, improving the precision and efficacy of treatment. Bellintumab is a bispecific antibody that binds to CD3-positive T cells on one end and CD19-positive B cells on the other end. This structure gives it a two-way mechanism of action. First, it targets cancer cells by connecting T cells and B cells. CD19 is a specific antigen on the surface of B cells. It is widely expressed in B-cell acute lymphoblastic leukemia (B-ALL). Therefore, belintuzumab can accurately identify B-ALL cells.